Europe Becomes First to Clear Moderna's Combo Flu-COVID Vaccine

Moderna's European approval of mCOMBRIAX represents a watershed moment as the first authorized combination vaccine for both flu and COVID-19, promising to streamline immunization for vulnerable populations. The US regulatory delay, however, highlights a significant divergence between American and European approval processes and raises questions about domestic vaccine innovation timelines and market competitiveness.